ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) Short Interest Update

Posted by Irma Garcia on Jun 15th, 2024

ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS – Get Free Report) saw a significant increase in short interest during the month of May. As of May 31st, there was short interest totalling 16,300 shares, an increase of 29.4% from the May 15th total of 12,600 shares. Based on an average daily trading volume, of 7,200 shares, the short-interest ratio is currently 2.3 days.

Hedge Funds Weigh In On ProShares UltraShort Nasdaq Biotechnology

An institutional investor recently bought a new position in ProShares UltraShort Nasdaq Biotechnology stock. IMC Chicago LLC bought a new position in shares of ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 15,001 shares of the company’s stock, valued at approximately $271,000. IMC Chicago LLC owned 3.19% of ProShares UltraShort Nasdaq Biotechnology at the end of the most recent quarter.

ProShares UltraShort Nasdaq Biotechnology Stock Performance

Shares of BIS traded up $0.23 during mid-day trading on Friday, reaching $17.07. The company’s stock had a trading volume of 57 shares, compared to its average volume of 16,034. ProShares UltraShort Nasdaq Biotechnology has a 1-year low of $16.37 and a 1-year high of $26.51. The business has a 50-day simple moving average of $18.41 and a two-hundred day simple moving average of $18.45.

ProShares UltraShort Nasdaq Biotechnology Announces Dividend

The company also recently announced a dividend, which was paid on Wednesday, March 27th. Stockholders of record on Thursday, March 21st were paid a dividend of $0.1586 per share. The ex-dividend date of this dividend was Wednesday, March 20th.

ProShares UltraShort Nasdaq Biotechnology Company Profile

(Get Free Report)

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks investment results for a single day only, not for longer periods. The Fund seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from twice (200%) the return of the Nasdaq Biotechnology Index (the Index) for that period.